ОБЗОР

Влияние коронавирусной инфекции (COVID-19) на сердечно-сосудистую систему

Информация об авторах

Российский национальный исследовательский медицинский университет имени Н. И. Пирогова, Москва, Россия

Для корреспонденции: Ларина Вера Николаевна
ул. Островитянова, д. 1, г. Москва, 117997; ur.liam@vaniral

Информация о статье

Благодарности: член-корреспонденту РАН, профессору, д. м. н., профессору кафедры патофизиологии и клинической патофизиологии лечебного факультета ФГАОУ ВО РНИМУ имени Н. И. Пирогова Минздрава России Геннадию Васильевичу Порядину за ценные критические замечания.

Вклад авторов: В. Н. Ларина — разработка концепции, планирование исследования, анализ литературы, интерпретация данных, написание текста; М. Г. Головко и В. Г. Ларин — планирование исследования, анализ литературы, интерпретация данных, подготовка черновика рукописи.

Статья получена: 03.04.2020 Статья принята к печати: 17.04.2020 Опубликовано online: 18.04.2020
|
  1. Fauci AS, Lane HC, Redfield RR. Covid-19: navigating the uncharted. N Engl J Med. 2020. DOI: 10.1056/NEJMe2002387.
  2. Cowan LT, Lutsey PL, Pankow JS, Matsushita K, Ishigami J, Lakshminarayan K. Inpatient and outpatient infection as a trigger of cardiovascular disease: the ARIC study. J Am Heart Assoc. 2018; 7 (22): e009683-e009683. DOI: 10.1161/ JAHA.118.009683.
  3. Su S, Wong G, Shi W, et al. Epidemiology, genetic recombination, and pathogenesis of coronaviruses. Trends Microbiol. 2016; 24 (6): 490–502. DOI: 10.1016/j.tim.2016.03.003.
  4. Song HD, Tu CC, Zhang GW, Wang SY, Zheng K, et al. Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human. Proceedings of the National Academy of Sciences. 2005; 102 (7) 2430–2435; DOI: 10.1073/ pnas.0409608102.
  5. Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015; 7 (3): 996–1019. DOI: 10.3390/v7030996.
  6. Nagai T, Nitta K, Kanasaki M, Kova D, Kanasaki K. The biological significance of angiotensin-converting enzyme inhibition to combat kidney fibrosis. Clin Exp Nehrol. 2015; 19 (1): 65–74.
  7. Yeo C, Kaushal S, Yeo D. Enteric involvement of coronaviruses: is faecal-oral transmission of SARS-CoV-2 possible? Lancet Gastroenterol Hepatol. 2020; 5 (4): 335–7. DOI: 10.1016/S2468- 1253(20)30048-0.
  8. Assiri A, Al-Tawfiq JA, Al-Rabeeah AA, et al. Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study. Lancet Infect Dis. 2013; (13): 752–61.
  9. Zhou J, Li C, Zhao G, et al. Human intestinal tract serves as an alternative infection route for Middle East respiratory syndrome coronavirus. Sci Adv. 2017; (3): eaao4966.
  10. Chan JF-W, Yuan S, Kok K-H, et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet. 2020; 395 (10223): 514–23. DOI: 10.1016/S0140-6736(20)30154-9.
  11. Backer JA, Klinkenberg D, Wallinga J. Incubation period of 2019 novel coronavirus (2019-nCoV) infections among travellers from Wuhan, China, 20–28 January 2020. Euro Surveill. 2020; 25 (5): 2000062. DOI: 10.2807/1560-7917.ES.2020.25.5.2000062.
  12. Otter JA, Donskey C, Yezli S, Douthwaite S, Goldenberg SD, Weber DJ. Transmission of SARS and MERS coronaviruses and influenza virus in healthcare settings: the possible role of dry surface contamination. J Hosp Infect. 2016; 92 (3): 235–50. DOI: 10.1016/j.jhin.2015.08.027.
  13. Madjid M, Safavi-Naeini P, Solomon SD, Vardeny O. Potential Effects of Coronaviruses on the Cardiovascular System: A Review. JAMA Cardiol. Published online March 27, 2020. DOI: 10.1001/ jamacardio.2020.1286.
  14. Berry M, Gamieldien J, Fielding BC. Identification of new respiratory viruses in the new millennium. Viruses. 2015; 7 (3): 996–1019. DOI: 10.3390/v7030996.
  15. US Centers for Disease Control and Prevention COVID-19 Response Team. Severe Outcomes Among Patients with Coronavirus Disease 2019 (COVID-19): United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. Published online March 18, 2020. DOI: 10.15585/mmwr.mm6912e2.
  16. Wu C, Chen X, Cai Y, Xia J, Zhou X, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. https://doi.org/10.1001/ jamainternmed.2020.0994.
  17. С. Warren-Gash, et al. Influenza as a trigger for acute myocardial infarction or death from cardiovascular disease: a systematic review. Lancet Infect Dis. 2009; 9 (10): 601–10.
  18. Collins S. Excess mortality from causes other than influenza and pneumonia during influenza epidemics. Public Health Rep. 1932; (47): 2159–89.
  19. Peiris JS, Chu CM, Cheng VC, et al. HKU/UCH SARS Study Group. Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet. 2003; 361 (9371): 1767–72. DOI: 10.1016/S0140- 6736(03)13412-5.
  20. Kwong JC, Schwartz KL, Campitelli MA, et al. Acute myocardial infarction after laboratory-confirmed influenza infection. N Engl J Med. 2018; 378 (4): 345–53. DOI: 10.1056/NEJMoa1702090.
  21. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020; 395 (10223): 497–506. DOI: 10.1016/S0140-6736(20)30183-5.
  22. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020. DOI: 10.1056/ NEJMoa2002032.
  23. Inciardi RM, Lupi L, Zaccone G, et al. Cardiac involvement 1 with coronavirus 2019 (COVID-19) infection. JAMA Cardiol. 2020. DOI: 10.1001/jamacardio.2020.1096.
  24. Guo T, Fan Y, Chen M, et al. Association of cardiovascular disease and myocardial injury with outcomes of patients hospitalized with 2019-coronavirus disease (COVID-19). JAMA Cardiol. Published online March 27, 2020. DOI: 10.1001/jamacardio.2020.1017.
  25. Благова О. В., Недоступ А. В. Современные маски миокардита (от клинических синдромов к диагнозу). Российский кардиологический журнал. 2014; (5): 13–22. https://DOI. org/10.15829/1560-4071-2014-5-13-22.
  26. Благова О. В., Недоступ А. В., Коган Е. А., Седов В. П., Донников А. Е., Кадочникова В. В., и др. ДКМП как клинический синдром: результаты нозологической диагностики с применением биопсии миокарда и дифференцированного лечения у вирус- позитивных и вирус-негативных больных. Российский кардиологический журнал. 2016; (1): 7–19. https://doi.org/10.15829/1560-4071-2016-1-7-19.
  27. Shi S, Qin M, Shen B, et al. Cardiac injury in patients with corona virus disease 2019. JAMA Cardiol. Published online March 25, 2020. DOI: 10.1001/jamacardio.2020.0950.
  28. Cooper L, Baughman K, Feldman A, Frustaci A, Jessup M, Kuhl U, et al. The role of endomyocardial biopsy in the management of cardiovascular disease: a scientific statement from the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. Endorsed by the Heart Failure Society of America and the Heart Failure Association of the European Society of Cardiology. Journal of the American College of Cardiology. 2007; 50 (19): 1914–31.
  29. Vaduganathan M, Vardeny O, Michel M, McMurray J, Pfeffer M, Solomon S. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19. March 30, 2020; DOI: 10.1056/ NEJMsr2005760.
  30. Bavishi C, Maddox TM, Messerli FH. Coronavirus Disease 2019 (COVID-19) Infection and Renin Angiotensin System Blockers. JAMA Cardiol. Published online April 03, 2020. DOI: 10.1001/ jamacardio.2020.1282
  31. Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga AC, White HD. Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2018; 31 (4): 419– 23. DOI: 10.1080/08998280.2018.1499293
  32. de Simone G. Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. https://www.escardio.org/Councils/Council-on- Hypertension-(CHT)/News/position-statement-of-the-esc-council-on-hypertension-on-ace-inhibitors-and-ang.
  33. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. https://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-covid-19.
  34. Шляхто Е. В., Конради А. О., Арутюнов Г. П., Арутюнов А. Г., Баутин А. Е., Бойцов С. А., и др. Руководство по диагностике и лечению болезней системы кровообращения в контексте пандемии ООУЮ-19. Российский кардиологический журнал. 2020; 25 (3): 3801. DOI: 10.15829/1560-4071-2020-3-3801.
  35. Halliday BP, Wassall R, Lota AS, et al. Withdrawal of pharmacological treatment for heart failure in patients with recovered dilated cardiomyopathy (TRED-HF): an open-label, pilot, randomised trial. Lancet. 2019; (393): 61–73.
  36. Thomsen M, Lewinter C, Køber L. Varying effects of recommended treatments for heart failure with reduced ejection fraction: meta-analysis of randomized controlled trials in the ESC and ACCF/ AHA guidelines. ESC Heart Failure. 2016; (3): 235–44.
  37. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020; (181): 1–10. DOI: 10.1016/j.cell.2020.02.052.